Alix Steel and Paul Sweeney harness the power of Bloomberg Intelligence to analyze market news and provide in-depth company and industry research.
Novo Nordisk announced disappointing data from a phase III study on a novel obesity candidate, CagriSema. Roche announced a ...
Investor's Business Daily on MSN5h
Stock Market Correction: Trump Tariffs Triggers Sell-Off Despite Tame Inflation: Weekly ReviewThe major indexes suffered another week of sharp losses as Trump tariffs ramped up, shrugging off tame inflation.
Topline data were announced from a phase 3 trial evaluating CagriSema (cagrilintide/semaglutide) in overweight or obese patients with type 2 diabetes.
Novo Nordisk faces formidable challenges from Eli Lilly and new rivals, but its first-mover advantage and expanded ...
Denmark: CagriSema has demonstrated superior weight loss in adults with obesity or overweight and type 2 diabetes in the ...
AbbVie Inc. enters the obesity market with GUBamy, a promising amylin analog. Click here to find out why ABBV stock is a Buy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback